Compare AbbVie Inc (ABBV) vs SiTime Corporation (SITM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs SiTime Corporation — how do they compare? AbbVie Inc trades at $253.8 (market cap $449.91B), while SiTime Corporation trades at $598.1 (market cap $17.74B). The key difference: AbbVie Inc is far larger — about 25.4× SiTime Corporation's market cap, and AbbVie Inc pays a 2.72% dividend while SiTime Corporation pays none. Which is the better fit depends on your goals.
| ABBV | SITM | |
|---|---|---|
Market Cap | $449.91B | $17.74B |
Sector | Health | Technology |
52-Week High | $261.07 | $901.60 |
52-Week Low | $184.85 | $190.16 |
Enterprise Value | $513.38B | $16.95B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
SITM trades at $615.46, up 2.29% today, showing strong momentum with three consecutive quarterly earnings beats. The stock faces technical headwinds with a bearish moving average signal, while fundamentals reveal robust revenue growth but negative profitability metrics. Recent news highlights the completed acquisition of Renesas' timing business and strong AI-driven demand, with management raising full-year growth guidance to at least 80%.
The outlook remains promising due to accelerating AI infrastructure demand and strategic acquisitions, though investors face risks from negative profit margins and high valuation multiples. Analyst consensus is unanimously bullish with a $743.75 price target representing 21% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
